title: Improved outcome with multimodal treatment and imatinib rechallenge in advanced GIST.
authors: CRO Aviano National Cancer Institute, Experimental Oncology 1, via Gallini 2, 33081, Aviano, Italy, dgasparotto@cro.it.
authors: Daniela
authors: D
authors: Gasparotto
authors: Gianmaria
authors: G
authors: Miolo
authors: Elena
authors: E
authors: Torrisi
authors: Vincenzo
authors: V
authors: Canzonieri
authors: Giulio
authors: G
authors: Bertola
authors: Massimo
authors: M
authors: Libra
authors: Alessandra
authors: A
authors: Marzotto
authors: Roberta
authors: R
authors: Maestro
authors: Angela
authors: A
authors: Buonadonna
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D001549:Benzamides / Q000627:therapeutic use*; D017024:Chemotherapy, Adjuvant; D018450:Disease Progression; D046152:Gastrointestinal Stromal Tumors / Q000188:drug therapy* / Q000473:pathology / Q000601:surgery*; D006801:Humans; D000068877:Imatinib Mesylate; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy / Q000473:pathology / Q000601:surgery; D010879:Piperazines / Q000627:therapeutic use*; D011743:Pyrimidines / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000970:Antineoplastic Agents; D001549:Benzamides; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate